CN105456277A - 灵芝三萜酸活性部位在制备降血脂保健品和药物中的应用 - Google Patents
灵芝三萜酸活性部位在制备降血脂保健品和药物中的应用 Download PDFInfo
- Publication number
- CN105456277A CN105456277A CN201510933865.8A CN201510933865A CN105456277A CN 105456277 A CN105456277 A CN 105456277A CN 201510933865 A CN201510933865 A CN 201510933865A CN 105456277 A CN105456277 A CN 105456277A
- Authority
- CN
- China
- Prior art keywords
- ganoderma
- ethyl acetate
- dry powder
- acid
- application according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000222336 Ganoderma Species 0.000 title claims abstract description 115
- 239000002253 acid Substances 0.000 title claims abstract description 101
- 150000003648 triterpenes Chemical class 0.000 title claims abstract description 80
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 230000036541 health Effects 0.000 title claims abstract description 11
- 230000000055 hyoplipidemic effect Effects 0.000 title abstract description 6
- 229940079593 drug Drugs 0.000 title abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 75
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 48
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000000843 powder Substances 0.000 claims abstract description 32
- 102000004190 Enzymes Human genes 0.000 claims abstract description 27
- 108090000790 Enzymes Proteins 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000002024 ethyl acetate extract Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000001816 cooling Methods 0.000 claims abstract description 6
- 239000003208 petroleum Substances 0.000 claims abstract description 6
- 239000000741 silica gel Substances 0.000 claims abstract description 6
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 6
- 238000004809 thin layer chromatography Methods 0.000 claims abstract description 6
- 230000007071 enzymatic hydrolysis Effects 0.000 claims abstract description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims description 74
- 210000004369 blood Anatomy 0.000 claims description 25
- 239000008280 blood Substances 0.000 claims description 25
- 229940088598 enzyme Drugs 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000004519 grease Substances 0.000 claims description 10
- 108090000145 Bacillolysin Proteins 0.000 claims description 8
- 108010059892 Cellulase Proteins 0.000 claims description 8
- 102000035092 Neutral proteases Human genes 0.000 claims description 8
- 108091005507 Neutral proteases Proteins 0.000 claims description 8
- 229940106157 cellulase Drugs 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000012567 medical material Substances 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 5
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 5
- 229960001866 silicon dioxide Drugs 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 abstract description 9
- 230000007935 neutral effect Effects 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 2
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 abstract 3
- 229930182735 Ganoderic acid Natural products 0.000 abstract 3
- 230000002255 enzymatic effect Effects 0.000 abstract 2
- 239000000413 hydrolysate Substances 0.000 abstract 2
- 238000005238 degreasing Methods 0.000 abstract 1
- 238000004821 distillation Methods 0.000 abstract 1
- 230000000415 inactivating effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 16
- 241000699684 Meriones unguiculatus Species 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 description 12
- 241000699694 Gerbillinae Species 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 10
- 108010028554 LDL Cholesterol Proteins 0.000 description 10
- 238000010171 animal model Methods 0.000 description 10
- 238000011160 research Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- -1 triterpenoid compound Chemical class 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002798 spectrophotometry method Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 238000013232 NAFLD rodent model Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 101000904460 Encephalitozoon cuniculi (strain GB-M1) Probable glycerol-3-phosphate dehydrogenase Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241001489090 Ganoderma japonicum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 238000013231 NASH rodent model Methods 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 动物数 | 初始体重(g) | 中期体重(g) | 末期体重(g) |
空白对照组 | 10 | 51.09±2.76 | 59.87±5.11 | 66.23±3.72 |
模型对照组 | 10 | 49.21±5.17 | 62.10±6.18 | 67.28±2.76 |
灵芝三萜酸30mg/kg | 10 | 53.17±3.23 | 58.99±1.66 | 71.22±2.49 |
灵芝三萜酸70mg/kg | 10 | 51.33±3.96 | 61.22±2.84 | 68.58±3.47 |
灵芝三萜酸110mg/kg | 10 | 52.87±6.92 | 60.38±3.27 | 73.12±5.81 |
灵芝三萜酸150mg/kg | 10 | 50.37±4.63 | 58.99±1.20 | 69.43±2.17 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510933865.8A CN105456277B (zh) | 2015-12-14 | 2015-12-14 | 灵芝三萜酸活性部位在制备降血脂保健品和药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510933865.8A CN105456277B (zh) | 2015-12-14 | 2015-12-14 | 灵芝三萜酸活性部位在制备降血脂保健品和药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105456277A true CN105456277A (zh) | 2016-04-06 |
CN105456277B CN105456277B (zh) | 2018-07-31 |
Family
ID=55594743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510933865.8A Active CN105456277B (zh) | 2015-12-14 | 2015-12-14 | 灵芝三萜酸活性部位在制备降血脂保健品和药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105456277B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106722875A (zh) * | 2016-12-07 | 2017-05-31 | 盐城工学院 | 一种灵芝三萜的提取方法及灵芝保健品 |
CN108802255A (zh) * | 2018-06-15 | 2018-11-13 | 福建仙芝楼生物科技有限公司 | 测定复方制剂中灵芝酸a和灵芝三萜类成分含量的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772448A (zh) * | 2012-08-15 | 2012-11-14 | 苏州菩芸生物科技有限公司 | 灵芝三萜提取方法 |
CN104761612A (zh) * | 2015-02-03 | 2015-07-08 | 安发(福建)生物科技有限公司 | 灵芝三萜酸提取分离工艺方法 |
-
2015
- 2015-12-14 CN CN201510933865.8A patent/CN105456277B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772448A (zh) * | 2012-08-15 | 2012-11-14 | 苏州菩芸生物科技有限公司 | 灵芝三萜提取方法 |
CN104761612A (zh) * | 2015-02-03 | 2015-07-08 | 安发(福建)生物科技有限公司 | 灵芝三萜酸提取分离工艺方法 |
Non-Patent Citations (1)
Title |
---|
李国华等: "灵芝三萜类化合物研究进展", 《中草药》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106722875A (zh) * | 2016-12-07 | 2017-05-31 | 盐城工学院 | 一种灵芝三萜的提取方法及灵芝保健品 |
CN108802255A (zh) * | 2018-06-15 | 2018-11-13 | 福建仙芝楼生物科技有限公司 | 测定复方制剂中灵芝酸a和灵芝三萜类成分含量的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105456277B (zh) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103417601B (zh) | 一种具有调节血脂作用的药物组合物及其用途 | |
CN1330670C (zh) | 玉竹多糖的提取方法、药物制剂制备方法及其用途 | |
US10093695B2 (en) | Sterol derivative, preparation method therefor and use thereof | |
CN1687340A (zh) | 白刺籽油的超临界co2萃取工艺及其在降血脂中的应用 | |
CN105456277A (zh) | 灵芝三萜酸活性部位在制备降血脂保健品和药物中的应用 | |
CN101849950A (zh) | 救必应酸在制备调血脂的药物中的应用 | |
CN104434930B (zh) | 包含24‑乙酰泽泻醇A和23‑乙酰泽泻醇B的组合物及其在调血脂、制备HMG‑CoA抑制剂上的应用 | |
CN104055947B (zh) | 一种含有葡萄提取物的中药组合物及制备方法 | |
CN102477453A (zh) | 一种从黄杞叶中制备花旗松素单体的方法及用途 | |
CN106866691A (zh) | 一种提取芝麻素的方法 | |
CN101342186B (zh) | 五环三萜皂苷化合物的用途 | |
CN103360452A (zh) | 甜瓜蒂四环三萜葫芦素类化合物的制备和应用 | |
CN106924299B (zh) | 一种黑木耳提取物及其在降血脂药物及保健食品中的应用 | |
CN105193824B (zh) | 一种灵芝三萜酸活性部位及其制备方法和应用 | |
CN108164574B (zh) | 小花清风藤中的一种化合物及其制备方法与应用 | |
CN107028965A (zh) | 芫根苷或其衍生物在制备降脂药物中的应用和产品 | |
CN103880913B (zh) | 一种具有保肝作用的化合物及其应用 | |
CN104815011A (zh) | 一种用于降血脂的蒙药材荜拨提取物 | |
CN105012352B (zh) | Equisetin在制备用于防治和治疗代谢综合症药物方面的用途 | |
WO2013155997A1 (zh) | 一种调节血脂的红曲川芎药物组合及其制备方法 | |
CN102824391B (zh) | 马兰在制备降血脂药物或功能性食品中的应用 | |
CN103505481A (zh) | 一种含有植物甾醇的降血脂组合物及制备方法 | |
CN108084009A (zh) | 小花清风藤中的一种化合物及其制备方法与应用 | |
CN102319273A (zh) | 北美盐角草活性总皂苷提取物及其制备方法和瘦身减肥的用途 | |
CN103864883B (zh) | 具有保肝护肝作用的三萜皂苷化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 310013 No. 182 Tianmu Mountain Road, Zhejiang, Hangzhou Patentee after: HANGZHOU MEDICAL College Address before: 310013 No. 182 Tianmu Mountain Road, Zhejiang, Hangzhou Patentee before: ZHEJIANG ACADEMY OF MEDICAL SCIENCES |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230607 Address after: 310000 No. 182, Tianmushan Road, Xihu District, Hangzhou City, Zhejiang Province Patentee after: Zhejiang Pufa Technology Development Center Address before: 310013 No. 182 Tianmu Mountain Road, Zhejiang, Hangzhou Patentee before: HANGZHOU MEDICAL College |
|
TR01 | Transfer of patent right |